Abstract
Hepatitis B virus infection (HBV) is a significant global health problem. Despite the success of universal hepatitis B vaccination in many countries, more than 350 million individuals worldwide are chronically infected and 15- 40% of those will develop cirrhosis and/or hepatocellular carcinoma if left untreated. Available therapies for chronic hepatitis B (CHB) infection are effective at decreasing viremia and improving measured clinical outcomes, however, no single therapy is optimal. As such, alternative drug therapies and the investigation of their role in the management of CHB are warranted. Significant improvements in the understanding of the HBV life cycle, viral genomics, and virus-host interactions continue to lead to the development of novel viral targets and immune modulators. Currently, two major classes of agents are utilized in CHB: the interferons and the nucleos(t)ide analogues. Each agent has individual advantages and drawbacks. The development of specific antiviral therapy has led to the emergence of HBV drug-resistant strains that has limited the long-term therapeutic potential of available agents. This necessitates the development of new agents that target both wild-type and drug-resistant strains. Further understanding of the basic mechanisms and clinical nuances of drug therapy is warranted. As most novel therapies are in the earliest stages of clinical development and testing, in the near future, treatment will continue to be long-term and likely involve the use of combination therapies to prevent viral resistance. In this review, we will highlight the HBV life cycle and genome, focusing in on current and potential novel antiviral drug targets as well as the benefits and clinical challenges with these therapies.
Keywords: HBV, interferon, drug resistance, nucleoside/nucleotide analogues, lamivudine, entecavir, adefovir
Infectious Disorders - Drug Targets
Title: Drug Targets in Hepatitis B Virus Infection
Volume: 9 Issue: 2
Author(s): Lance L. Stein and Rohit Loomba
Affiliation:
Keywords: HBV, interferon, drug resistance, nucleoside/nucleotide analogues, lamivudine, entecavir, adefovir
Abstract: Hepatitis B virus infection (HBV) is a significant global health problem. Despite the success of universal hepatitis B vaccination in many countries, more than 350 million individuals worldwide are chronically infected and 15- 40% of those will develop cirrhosis and/or hepatocellular carcinoma if left untreated. Available therapies for chronic hepatitis B (CHB) infection are effective at decreasing viremia and improving measured clinical outcomes, however, no single therapy is optimal. As such, alternative drug therapies and the investigation of their role in the management of CHB are warranted. Significant improvements in the understanding of the HBV life cycle, viral genomics, and virus-host interactions continue to lead to the development of novel viral targets and immune modulators. Currently, two major classes of agents are utilized in CHB: the interferons and the nucleos(t)ide analogues. Each agent has individual advantages and drawbacks. The development of specific antiviral therapy has led to the emergence of HBV drug-resistant strains that has limited the long-term therapeutic potential of available agents. This necessitates the development of new agents that target both wild-type and drug-resistant strains. Further understanding of the basic mechanisms and clinical nuances of drug therapy is warranted. As most novel therapies are in the earliest stages of clinical development and testing, in the near future, treatment will continue to be long-term and likely involve the use of combination therapies to prevent viral resistance. In this review, we will highlight the HBV life cycle and genome, focusing in on current and potential novel antiviral drug targets as well as the benefits and clinical challenges with these therapies.
Export Options
About this article
Cite this article as:
Stein L. Lance and Loomba Rohit, Drug Targets in Hepatitis B Virus Infection, Infectious Disorders - Drug Targets 2009; 9 (2) . https://dx.doi.org/10.2174/187152609787847677
DOI https://dx.doi.org/10.2174/187152609787847677 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preclinical and Clinical Efficacy of the Bisphosphonate Ibandronate in Cancer Treatment
Current Clinical Pharmacology The Role of a Disturbed Arginine/NO Metabolism in the Onset of Cancer Cachexia: A Working Hypothesis
Current Medicinal Chemistry Rheb/mTOR Activation and Regulation in Cancer: Novel Treatment Strategies beyond Rapamycin
Current Drug Targets A Review on the Management of Small Renal Masses: Active Surveillance Versus Surgery
Anti-Cancer Agents in Medicinal Chemistry A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry Clinical Pharmacogenetics in Oncology: the Paradigm of Molecular Targeted Therapies
Current Pharmaceutical Design Methylenedioxy- and Ethylenedioxy-Fused Indolocarbazoles: Potent Human Topoisomerase I Inhibitors and Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Chemoprevention of Colorectal Carcinogenesis by Natural Anti-Inflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Indole Derivatives as Anticancer Agents for Breast Cancer Therapy: A Review
Anti-Cancer Agents in Medicinal Chemistry Molecular Evidence of Cryptotanshinone for Treatment and Prevention of Human Cancer
Anti-Cancer Agents in Medicinal Chemistry Nanomedicine: Potential Devices for Diagnostics
Recent Patents on Nanomedicine Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) – an Introduction for Biologists
Current Proteomics Cutting the Limits of Aminobisphosphonates: New Strategies for the Potentiation of their Anti-Tumour Effects
Current Cancer Drug Targets Developments in the Application of 1,2,3-Triazoles in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Patent Selections
Recent Patents on Biomarkers Identification and Induction of Cytochrome P450s Involved in the Metabolism of Flavone-8-Acetic Acid in Mice
Drug Metabolism Letters Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer
Reviews on Recent Clinical Trials Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma
Current Drug Targets Review of Clinic Trials: Agents Targeting c-Met
Reviews on Recent Clinical Trials 2-Chloroadenosine and Human Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry